Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Oxypyrronium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.56 |
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 0.56 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.56 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.56 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.56 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | HRH1 | P35367 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxypyrronium SCHEMBL29388831 | 0.99 | POLB (0.57) | CHRM2CHRM3CHRM1KCNH2CHRM4 | |
| Poldine SCHEMBL1641786 | 0.83 | CHRM2 (0.55) | CHRM2CHRM3CHRM1KCNH2CHRM4 | |
| SCHEMBL5252511 | 0.83 | POLB (0.51) | CHRM2CHRM3CHRM1KCNH2CHRM4 | |
| SCHEMBL1086651 | 0.83 | POLB (0.51) | CHRM2CHRM3CHRM1KCNH2CHRM4 | |
| SCHEMBL1086653 | 0.83 | POLB (0.51) | CHRM2CHRM3CHRM1KCNH2CHRM4 | |
| SCHEMBL1086654 | 0.83 | POLB (0.51) | CHRM2CHRM3CHRM1KCNH2CHRM4 | |
| SCHEMBL1086380 | 0.83 | POLB (0.50) | CHRM2CHRM3CHRM1KCNH2CHRM4 | |
| SCHEMBL5245016 | 0.83 | POLB (0.50) | CHRM2CHRM3CHRM1KCNH2CHRM4 | |
| SCHEMBL1086386 | 0.83 | POLB (0.50) | CHRM2CHRM3CHRM1KCNH2CHRM4 | |
| SCHEMBL1086383 | 0.83 | POLB (0.50) | CHRM2CHRM3CHRM1KCNH2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117196693-B | Logistics demand prediction method for urban underground traffic | 西南交通大学 | 2024-03-26 | — | — | CN | claimed |
| CN-117196693-A | Logistics demand prediction method for urban underground traffic | 西南交通大学 | 2023-12-08 | — | — | CN | claimed |
| EP-4088717-A1 | USE AND COMPOSITION FOR TREATING DEMENTIA | Chase Pharmaceuticals Corporation (US) | 2022-11-16 | — | — | EP | disclosed |
| EP-4035668-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | Chase Pharmaceuticals Corporation (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20210128528-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | AXOVANT SCIENCES GMBH (CH) | 2021-05-06 | — | — | US | disclosed |
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-10-17 | — | — | US | disclosed |
| US-10307409-B2 | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190091214-A1 | USE AND COMPOSITION FOR TREATING DEMENTIA | CHASE PHARMACEUTICALS CORP (US) | 2019-03-28 | — | — | US | disclosed |
| WO-2019033068-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | AXOVANT SCIENCES GMBH (CH) | 2019-02-14 | — | — | WO | disclosed |
| US-20190046506-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | AXOVANT SCIENCES GMBH (CH) | 2019-02-14 | — | — | US | disclosed |
| US-20190000826-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-01-03 | — | — | US | disclosed |
| US-6180823-B1 | CONDENSING SUBSTITUTED ACETALDEHYDE WITH ENANTIOMER OF MANDELIC ACID TO PROVIDE 5-PHENYL-1,3-DIOXOLAN-4-ONE, CONDENSING WITH CYCLOHEXANONE, DEHYDRATING PRODUCT, HYDROLYZING, REDUCING TO ALPHA-CYCLOHEXYLPHENYLGLYCOLIC ACID | SEPRACOR INC. | 2001-01-30 | — | — | US | disclosed |
| US-6140529-A | Synthesis of optically active cyclohexylphenylglycolate esters | SEPRACOR INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-6090971-A | Resolution process for cyclohexylphenyl glycolic acid | SEPRACOR INC. (US) | 2000-07-18 | — | — | US | disclosed |
| WO-2000027786-A1 | STEREOSELECTIVE PROCESS FOR PREPARING (CYCLO)ALKYL PHENYLGLYCOLIC ACIDS | SEPRACOR INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000023414-A2 | SYNTHESIS OF OPTICALLY ACTIVE CYCLOHEXYLPHENYLGLYCOLIC ACID AND ITS ESTERS | SEPRACOR INC. (US) | 2000-04-27 | — | — | WO | disclosed |
| US-6025177-A | ENANTIOSELECTIVE SYNTHESIS OF CHIRAL ALPHA-HYDROXYCARBOXYLATE BY REACTING A PROCHIRAL ALPHA-KETOCARBOXYLIC ACID WITH A SINGLE ENANTIOMER OF AN N-SUBSTITUTED VICINAL AMINOALCOHOL OF SPECIFIC CYCLOHYDROCARBONS TO FORM ALPHA-HYDROXYCARBOXYLATE | SEPRACOR INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-6013830-A | CHEMICAL INTERMEDIATES FOR OXYBUTYNIN, OXYPHENCYCLIMINE, OXYPHENONIUM BROMIDE, OXYPYRRONIUM BROMIDE, AND OXYSONIUM IODIDE, FOR WHICH CYCLOHEXYLPHENYLGLYCOLIC ACID (CHPGA) IS OF SPECIAL INTEREST; STEREOSELECTIVITY | SEPRACOR INC. (US) | 2000-01-11 | — | — | US | disclosed |
| US-5973182-A | Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters | SEPRACOR INC. (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1999050205-A2 | ASYMMETRIC GRIGNARD SYNTHESIS WITH CYCLIC 1,2 AMINOALCOHOLS | SEPRACOR INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHRM3, CHRM2, CHRM4 | CHRM2 2/4885CHRM3 1/4885CHRM1 5/4885 |
| US-10307409-B2 | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system | CHRM3, CHRM2, CHRM4 | CHRM2 2/4885CHRM3 1/4885CHRM1 5/4885 |
| US-20190000826-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | ACHE, CHRNA5, SNCA | CHRM2 46/4885CHRM3 32/4885CHRM1 60/4885 |
| US-20190091214-A1 | USE AND COMPOSITION FOR TREATING DEMENTIA | ACHE, BCHE, CHAT | CHRM2 11/4885CHRM3 18/4885CHRM1 25/4885 |
| US-20210128528-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | HTR2A, HTR1A, HTR3B | CHRM2 251/4885CHRM3 299/4885CHRM1 369/4885 |
| US-20190046506-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | HTR2A, HTR1A, HTR3B | CHRM2 251/4885CHRM3 299/4885CHRM1 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.